Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina
- Autores
- Rodeles Antonelli, Luz María; Peverengo, Luz María; Benítez, Romina; Benzaquen, Nadia; Serravalle, Priscila; Long, Ana Karina; Ferreira, Virginia; Benitez, Agostina Daiana; Zunino, Luisina; Lizarraga, Camila; Vicco, Miguel Hernán
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Objective. To evaluate the seroprevalence of COVID-19 infection in pauci-symptomatic and asymptomatic people, the associated epidemiological factors, and IgG antibody kinetic over a 5-month period to get a better knowledge of the disease transmissibility and the rate of susceptible persons that might be infected. Methods. Seroprevalence was evaluated by a cross-sectional study based on the general population of Santa Fe, Argentina (non-probabilistic sample) carried out between July and November 2020. A subgroup of 20 seropositive individuals was followed-up to analyze IgG persistence. For the IgG anti-SARS-CoV-2 antibodies detection, the COVID-AR IgG® ELISA kit was used. Results. 3 000 individuals were included conforming asymptomatic and pauci-symptomatic groups (n=1 500 each). From the total sample, only 8.83% (n=265) presented reactivity for IgG anti-SARS-CoV-2. A significant association was observed between positive anti-SARS-CoV-2 IgG and a history of contact with a confirmed case; the transmission rate within households was approximately 30%. In the pauci-symptomatic group, among the seropositive ones, anosmia and fever presented an OR of 16.8 (95% CI 9.5-29.8) and 2.7 (95% CI 1.6-4.6), respectively (p <0.001). In asymptomatic patients, IgG levels were lower compared to pauci-symptomatic patients, tending to decline after 4 months since the symptoms onset. Conclusion. We observed a low seroprevalence, suggestive of a large population susceptible to the infection. Anosmia and fever were independent significant predictors for seropositivity. Asymptomatic patients showed lower levels of antibodies during the 5-month follow-up. IgG antibodies tended to decrease over the end of this period regardless of symptoms.
Fil: Rodeles Antonelli, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Peverengo, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Benítez, Romina. Centro de Especialidades Médicas; Argentina
Fil: Benzaquen, Nadia. Servicio de Cardiología Sanatorio de Diagnóstico y Tratamiento; Argentina
Fil: Serravalle, Priscila. Centro de Especialidades Médicas; Argentina
Fil: Long, Ana Karina. Centro de Especialidades Médicas; Argentina
Fil: Ferreira, Virginia. Centro de Especialidades Médicas; Argentina
Fil: Benitez, Agostina Daiana. Centro de Especialidades Médicas; Argentina
Fil: Zunino, Luisina. Centro de Especialidades Médicas; Argentina
Fil: Lizarraga, Camila. Centro de Especialidades Médicas; Argentina
Fil: Vicco, Miguel Hernán. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina - Materia
-
ANOSMIA
ARGENTINA
ASYMPTOMATIC DISEASES
EPIDEMIOLOGY
SARS-COV-2
SEROPREVALENCE
COVID-19 - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/152097
Ver los metadatos del registro completo
| id |
CONICETDig_b32da052895faff31c444ec732d851cb |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/152097 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in ArgentinaRodeles Antonelli, Luz MaríaPeverengo, Luz MaríaBenítez, RominaBenzaquen, NadiaSerravalle, PriscilaLong, Ana KarinaFerreira, VirginiaBenitez, Agostina DaianaZunino, LuisinaLizarraga, CamilaVicco, Miguel HernánANOSMIAARGENTINAASYMPTOMATIC DISEASESEPIDEMIOLOGYSARS-COV-2SEROPREVALENCECOVID-19https://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Objective. To evaluate the seroprevalence of COVID-19 infection in pauci-symptomatic and asymptomatic people, the associated epidemiological factors, and IgG antibody kinetic over a 5-month period to get a better knowledge of the disease transmissibility and the rate of susceptible persons that might be infected. Methods. Seroprevalence was evaluated by a cross-sectional study based on the general population of Santa Fe, Argentina (non-probabilistic sample) carried out between July and November 2020. A subgroup of 20 seropositive individuals was followed-up to analyze IgG persistence. For the IgG anti-SARS-CoV-2 antibodies detection, the COVID-AR IgG® ELISA kit was used. Results. 3 000 individuals were included conforming asymptomatic and pauci-symptomatic groups (n=1 500 each). From the total sample, only 8.83% (n=265) presented reactivity for IgG anti-SARS-CoV-2. A significant association was observed between positive anti-SARS-CoV-2 IgG and a history of contact with a confirmed case; the transmission rate within households was approximately 30%. In the pauci-symptomatic group, among the seropositive ones, anosmia and fever presented an OR of 16.8 (95% CI 9.5-29.8) and 2.7 (95% CI 1.6-4.6), respectively (p <0.001). In asymptomatic patients, IgG levels were lower compared to pauci-symptomatic patients, tending to decline after 4 months since the symptoms onset. Conclusion. We observed a low seroprevalence, suggestive of a large population susceptible to the infection. Anosmia and fever were independent significant predictors for seropositivity. Asymptomatic patients showed lower levels of antibodies during the 5-month follow-up. IgG antibodies tended to decrease over the end of this period regardless of symptoms.Fil: Rodeles Antonelli, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; ArgentinaFil: Peverengo, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; ArgentinaFil: Benítez, Romina. Centro de Especialidades Médicas; ArgentinaFil: Benzaquen, Nadia. Servicio de Cardiología Sanatorio de Diagnóstico y Tratamiento; ArgentinaFil: Serravalle, Priscila. Centro de Especialidades Médicas; ArgentinaFil: Long, Ana Karina. Centro de Especialidades Médicas; ArgentinaFil: Ferreira, Virginia. Centro de Especialidades Médicas; ArgentinaFil: Benitez, Agostina Daiana. Centro de Especialidades Médicas; ArgentinaFil: Zunino, Luisina. Centro de Especialidades Médicas; ArgentinaFil: Lizarraga, Camila. Centro de Especialidades Médicas; ArgentinaFil: Vicco, Miguel Hernán. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; ArgentinaOrganización Panamericana de la Salud2021-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/152097Rodeles Antonelli, Luz María; Peverengo, Luz María; Benítez, Romina; Benzaquen, Nadia; Serravalle, Priscila; et al.; Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina; Organización Panamericana de la Salud; Revista Panamericana de Salud Pública; 45; 1; 6-2021; 1-81020-4989CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.26633/RPSP.2021.66info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-11-12T09:34:07Zoai:ri.conicet.gov.ar:11336/152097instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-11-12 09:34:07.82CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina |
| title |
Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina |
| spellingShingle |
Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina Rodeles Antonelli, Luz María ANOSMIA ARGENTINA ASYMPTOMATIC DISEASES EPIDEMIOLOGY SARS-COV-2 SEROPREVALENCE COVID-19 |
| title_short |
Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina |
| title_full |
Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina |
| title_fullStr |
Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina |
| title_full_unstemmed |
Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina |
| title_sort |
Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina |
| dc.creator.none.fl_str_mv |
Rodeles Antonelli, Luz María Peverengo, Luz María Benítez, Romina Benzaquen, Nadia Serravalle, Priscila Long, Ana Karina Ferreira, Virginia Benitez, Agostina Daiana Zunino, Luisina Lizarraga, Camila Vicco, Miguel Hernán |
| author |
Rodeles Antonelli, Luz María |
| author_facet |
Rodeles Antonelli, Luz María Peverengo, Luz María Benítez, Romina Benzaquen, Nadia Serravalle, Priscila Long, Ana Karina Ferreira, Virginia Benitez, Agostina Daiana Zunino, Luisina Lizarraga, Camila Vicco, Miguel Hernán |
| author_role |
author |
| author2 |
Peverengo, Luz María Benítez, Romina Benzaquen, Nadia Serravalle, Priscila Long, Ana Karina Ferreira, Virginia Benitez, Agostina Daiana Zunino, Luisina Lizarraga, Camila Vicco, Miguel Hernán |
| author2_role |
author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
ANOSMIA ARGENTINA ASYMPTOMATIC DISEASES EPIDEMIOLOGY SARS-COV-2 SEROPREVALENCE COVID-19 |
| topic |
ANOSMIA ARGENTINA ASYMPTOMATIC DISEASES EPIDEMIOLOGY SARS-COV-2 SEROPREVALENCE COVID-19 |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
| dc.description.none.fl_txt_mv |
Objective. To evaluate the seroprevalence of COVID-19 infection in pauci-symptomatic and asymptomatic people, the associated epidemiological factors, and IgG antibody kinetic over a 5-month period to get a better knowledge of the disease transmissibility and the rate of susceptible persons that might be infected. Methods. Seroprevalence was evaluated by a cross-sectional study based on the general population of Santa Fe, Argentina (non-probabilistic sample) carried out between July and November 2020. A subgroup of 20 seropositive individuals was followed-up to analyze IgG persistence. For the IgG anti-SARS-CoV-2 antibodies detection, the COVID-AR IgG® ELISA kit was used. Results. 3 000 individuals were included conforming asymptomatic and pauci-symptomatic groups (n=1 500 each). From the total sample, only 8.83% (n=265) presented reactivity for IgG anti-SARS-CoV-2. A significant association was observed between positive anti-SARS-CoV-2 IgG and a history of contact with a confirmed case; the transmission rate within households was approximately 30%. In the pauci-symptomatic group, among the seropositive ones, anosmia and fever presented an OR of 16.8 (95% CI 9.5-29.8) and 2.7 (95% CI 1.6-4.6), respectively (p <0.001). In asymptomatic patients, IgG levels were lower compared to pauci-symptomatic patients, tending to decline after 4 months since the symptoms onset. Conclusion. We observed a low seroprevalence, suggestive of a large population susceptible to the infection. Anosmia and fever were independent significant predictors for seropositivity. Asymptomatic patients showed lower levels of antibodies during the 5-month follow-up. IgG antibodies tended to decrease over the end of this period regardless of symptoms. Fil: Rodeles Antonelli, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina Fil: Peverengo, Luz María. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina Fil: Benítez, Romina. Centro de Especialidades Médicas; Argentina Fil: Benzaquen, Nadia. Servicio de Cardiología Sanatorio de Diagnóstico y Tratamiento; Argentina Fil: Serravalle, Priscila. Centro de Especialidades Médicas; Argentina Fil: Long, Ana Karina. Centro de Especialidades Médicas; Argentina Fil: Ferreira, Virginia. Centro de Especialidades Médicas; Argentina Fil: Benitez, Agostina Daiana. Centro de Especialidades Médicas; Argentina Fil: Zunino, Luisina. Centro de Especialidades Médicas; Argentina Fil: Lizarraga, Camila. Centro de Especialidades Médicas; Argentina Fil: Vicco, Miguel Hernán. Universidad Nacional del Litoral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina |
| description |
Objective. To evaluate the seroprevalence of COVID-19 infection in pauci-symptomatic and asymptomatic people, the associated epidemiological factors, and IgG antibody kinetic over a 5-month period to get a better knowledge of the disease transmissibility and the rate of susceptible persons that might be infected. Methods. Seroprevalence was evaluated by a cross-sectional study based on the general population of Santa Fe, Argentina (non-probabilistic sample) carried out between July and November 2020. A subgroup of 20 seropositive individuals was followed-up to analyze IgG persistence. For the IgG anti-SARS-CoV-2 antibodies detection, the COVID-AR IgG® ELISA kit was used. Results. 3 000 individuals were included conforming asymptomatic and pauci-symptomatic groups (n=1 500 each). From the total sample, only 8.83% (n=265) presented reactivity for IgG anti-SARS-CoV-2. A significant association was observed between positive anti-SARS-CoV-2 IgG and a history of contact with a confirmed case; the transmission rate within households was approximately 30%. In the pauci-symptomatic group, among the seropositive ones, anosmia and fever presented an OR of 16.8 (95% CI 9.5-29.8) and 2.7 (95% CI 1.6-4.6), respectively (p <0.001). In asymptomatic patients, IgG levels were lower compared to pauci-symptomatic patients, tending to decline after 4 months since the symptoms onset. Conclusion. We observed a low seroprevalence, suggestive of a large population susceptible to the infection. Anosmia and fever were independent significant predictors for seropositivity. Asymptomatic patients showed lower levels of antibodies during the 5-month follow-up. IgG antibodies tended to decrease over the end of this period regardless of symptoms. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021-06 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/152097 Rodeles Antonelli, Luz María; Peverengo, Luz María; Benítez, Romina; Benzaquen, Nadia; Serravalle, Priscila; et al.; Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina; Organización Panamericana de la Salud; Revista Panamericana de Salud Pública; 45; 1; 6-2021; 1-8 1020-4989 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/152097 |
| identifier_str_mv |
Rodeles Antonelli, Luz María; Peverengo, Luz María; Benítez, Romina; Benzaquen, Nadia; Serravalle, Priscila; et al.; Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina; Organización Panamericana de la Salud; Revista Panamericana de Salud Pública; 45; 1; 6-2021; 1-8 1020-4989 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.26633/RPSP.2021.66 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Organización Panamericana de la Salud |
| publisher.none.fl_str_mv |
Organización Panamericana de la Salud |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1848597102470365184 |
| score |
12.976206 |